Clinical Research Directory
Browse clinical research sites, groups, and studies.
Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults
Sponsor: Tor Biering-Sørensen
Summary
The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of bivalent RSV prefusion F vaccine (RSV vaccine) in adults. Participants will be randomized 1:1 to either RSV vaccine or no RSV vaccine.
Official title: A Pragmatic Randomized Trial to Evaluate the Vaccine Effectiveness of Abrysvo® for Preventing RSV Hospitalizations in Adults Aged 18 Years or Above
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
690000
Start Date
2024-11-18
Completion Date
2028-08
Last Updated
2025-11-25
Healthy Volunteers
Yes
Conditions
Interventions
RSV prefusion F protein-based vaccine
For this arm, the RSV prefusion F protein-based vaccine Abrysvo® will be used
Locations (3)
Center for Translational Cardiology and Pragmatic Randomized Trials Department of Cardiology Copenhagen University Hospital - Herlev and Gentofte
Copenhagen, Denmark
Danske Lægers Vaccinations Service
Søborg, Denmark
General Public Health Directorate of Galician Health Service
Santiago de Compostela, A Coruña, Spain